Identification of Activated T Cells and the Suppressor/inducer Subset in Patients Suffering from Severe Aplastic Anemia

Overview

Journal Blut

Specialty Hematology

Date 1989 Jan 1

PMID 2521803

Authors

U Koller

W Hinterberger

L Gschwandtler

R Grumayer

O Majdic

W Knapp

Affiliations

Soon will be listed here.

Abstract

In patients with severe aplastic anemia (SAA), lymphocyte subpopulations were examined for the presence of HLA-DR and 2H4 (suppressor/inducer subset) antigen-expressing cells by flow cytometric analysis. Investigations were performed on peripheral blood lymphocytes before and after therapy with antithymocyte globulin (ATG) and methylprednisolone (MP), as well as on bone-marrow lymphocytes before therapy. Before treatment, only the absolute numbers of CD4+ T cells and the CD4+HLA-DR+/CD8+HLA-DR+ activated T cell ratio were significantly decreased (p less than 0.01 and p less than 0.001, respectively). Following successful ATG/MP treatment, a decrease in the CD4+/CD8+ T cell ratio was found. Regarding the suppressor/inducer subset, only absolute numbers of CD4+/2H4+ cells were somewhat higher in treated patients; the percentages were the same in all groups of patients. Studies performed on bone-marrow lymphocytes showed significantly decreased percentages of CD4+ and CD8+ T lymphocytes, which also express HLA-DR antigen. No significant changes in the distribution of activated T cells following ATG/MP therapy were found, suggesting that these cells play no major role in the pathogenesis of the disease.

References

Torok-Storb B, Sieff C, Storb R, Adamson J, Thomas E . In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization. Blood. 1980; 55(2):211-5. View

Hokland P, Kerndrup G, Griffin J, Ellegaard J . Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood. 1986; 67(4):898-902. View

Gluckman E, Marmont A, Speck B, Gordon-Smith E . Immunosuppressive treatment of aplastic anemia as an alternative treatment for bone marrow transplantation. Semin Hematol. 1984; 21(1):11-9. View

Koller U, Majdic O, Liszka K, Stockinger H, Pabinger-Fasching I, Lechner K . Lymphocytes of haemophilia patients treated with clotting factor concentrates display activation-linked cell-surface antigens. Clin Exp Immunol. 1985; 59(3):613-21. PMC: 1576942. View

Hinterberger W, Adolf G, Aichinger G, Dudczak R, Geissler K, Hocker P . Further evidence for lymphokine overproduction in severe aplastic anemia. Blood. 1988; 72(1):266-72. View

Freundlich B, Jimenez S . Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy. Clin Exp Immunol. 1987; 69(2):375-84. PMC: 1542423. View

Champlin R, Ho W, Gale R . Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med. 1983; 308(3):113-8. DOI: 10.1056/NEJM198301203080301. View

Pitzalis C, Kingsley G, Murphy J, Panayi G . Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol. 1987; 45(2):252-8. DOI: 10.1016/0090-1229(87)90040-7. View

Holter W, Majdic O, Liszka K, Stockinger H, Knapp W . Kinetics of activation antigen expression by in vitro-stimulated human T lymphocytes. Cell Immunol. 1985; 90(2):322-30. DOI: 10.1016/0008-8749(85)90197-2. View

10.

Speck B, Gratwohl A, Nissen C, Leibundgut U, Ruggero D, Osterwalder B . Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed). 1981; 282(6267):860-3. PMC: 1504686. DOI: 10.1136/bmj.282.6267.860. View

11.

Huang A, Mold N, Zhang S . Antithymocyte globulin stimulates human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987; 84(16):5942-6. PMC: 298979. DOI: 10.1073/pnas.84.16.5942. View

12.

Kuriyama K, Tomonaga M, Jinnai I, Matsuo T, Yoshida Y, Amenomori T . Reduced helper (OKT4+): suppressor (OKT8+) T ratios in aplastic anaemia: relation to immunosuppressive therapy. Br J Haematol. 1984; 57(2):329-36. DOI: 10.1111/j.1365-2141.1984.tb02902.x. View

13.

Platanias L, Gascon P, Bielory L, Griffith P, Nienhuis A, Young N . Lymphocyte phenotype and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia. Br J Haematol. 1987; 66(4):437-43. DOI: 10.1111/j.1365-2141.1987.tb01324.x. View

14.

Falcao R, Voltarelli J, Bottura C . T-lymphocyte subpopulations in the peripheral blood and bone marrow of patients with aplastic anemia. Blut. 1985; 50(2):103-7. DOI: 10.1007/BF00321173. View

15.

Bacigalupo A, Podesta M, Frassoni F, Piaggio G, Van Lint M, Raffo M . Generation of CFU-C suppressor T cells in vitro. V. A multistep process. Br J Haematol. 1982; 52(3):421-7. DOI: 10.1111/j.1365-2141.1982.tb03911.x. View

16.

Morimoto C, Letvin N, Distaso J, Brown H, Schlossman S . The cellular basis for the induction of antigen-specific T8 suppressor cells. Eur J Immunol. 1986; 16(2):198-204. DOI: 10.1002/eji.1830160216. View

17.

Bacigalupo A, Giordano D, Van Lint M, Vimercati R, Marmont A . Bolus methylprednisolone in severe aplastic anemia. N Engl J Med. 1979; 300(9):501-2. DOI: 10.1056/nejm197903013000919. View

18.

Reinherz E, Kung P, Pesando J, Ritz J, Goldstein G, Schlossman S . Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med. 1979; 150(6):1472-82. PMC: 2185738. DOI: 10.1084/jem.150.6.1472. View

19.

Hinterberger W, Hockern P, Schmidmeier W, Gadner H, Geissler K, Kos M . Treatment of severe aplastic anemia with combined immunosuppression (antithymocyte globulin and high-dose methylprednisolone). Acta Haematol. 1986; 76(4):196-201. DOI: 10.1159/000206055. View

20.

Zoumbos N, Ferris W, Hsu S, Goodman S, Griffith P, Sharrow S . Analysis of lymphocyte subsets in patients with aplastic anaemia. Br J Haematol. 1984; 58(1):95-105. DOI: 10.1111/j.1365-2141.1984.tb06063.x. View